Pulmonary hypertension in idiopathic pulmonary fibrosis: A review

Respiration

Volumn 82, Issue 3, 2011, Pages 294-304

  Pitsiou, Georgia ^a   Papakosta, Despina ^a   Bouros, Demosthenes ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Echocardiography; Idiopathic pulmonary fibrosis; Pulmonary function tests; Pulmonary hypertension; Six minute walk test

Indexed keywords

BIOLOGICAL MARKER; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; DIGITALIS; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; FIBROBLAST GROWTH FACTOR; ILOPROST; NITRIC OXIDE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; PROSTAGLANDIN E2; SILDENAFIL; TUMOR NECROSIS FACTOR ALPHA; UNIPROST; VASOACTIVE AGENT;

AEROSOL; ARTERIAL GAS; CARDIOPULMONARY HEMODYNAMICS; CELL PROLIFERATION; CHRONIC LUNG DISEASE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DOPPLER ECHOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE; FIBROSING ALVEOLITIS; FUNCTIONAL STATUS; GOLD STANDARD; HEART CATHETERIZATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPOXIC LUNG VASOCONSTRICTION; INTERSTITIAL LUNG DISEASE; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; LUNG LAVAGE; LUNG TRANSPLANTATION; LUNG VOLUME; MEAN ARTERIAL PRESSURE; NONHUMAN; OXYGEN THERAPY; PATHOGENESIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; PULSE OXIMETRY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SMOOTH MUSCLE FIBER; THORAX RADIOGRAPHY; THROMBOCYTE AGGREGATION; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE REGURGITATION; UPREGULATION;

ANTIHYPERTENSIVE AGENTS; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RISK FACTORS;

EID: 80051790295     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000327918     Document Type: Review

References (108)

1. American Thoracic Society/European Respiratory Society: International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
2. American Thoracic Society: Idiopathic pulmonary fibrosis: Diagnosis and treatment. International Consensus Statement. Am J Respir Crit Care Med 2000; 161: 646-664.
3. Raghu C, Weycker D, Edelsberg J, et al: Incidence and prevalence of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2006; 174: 810-816. (Pubitemid 44511663)
4. Coultas DB, Zumwalt RE, Black WC, Sobonya RE: The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967-972. (Pubitemid 24318021)
5. Karakatsani A, Papakosta D, Rapti A, et al; Hellenic Interstitial Lung Diseases Group: Epidemiology of interstitial lung diseases in Greece. Respir Med 2009; 103: 1122-1129.
6. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM: Predicting survival in idiopathic pulmonary fibrosis: Scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-1181. (Pubitemid 33052246)
7. Lama VN, Flaherty KR, Toews GB, et al: Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 1084-1090. (Pubitemid 37338937)
8. Flaherty KR, Andrei AC, Murray S, et al: Idiopathic pulmonary fibrosis: Prognostic value of changes in physiology and six-minutewalk test. Am J Respir Crit Care Med 2006; 174: 803-809. (Pubitemid 44511662)
9. Jezek V, Fucik J, Michaljanic A, Jezkova L: The prognostic significance of functional tests in cryptogenic fibrosing alveolitis. Bull Eur Physiopathol Respir 1980; 16: 711-720. (Pubitemid 11164124)
10. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF: Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752.
11. Nadrous HF, Pellikka PA, Krowka MJ, et al: Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393-2399. (Pubitemid 41507585)
12. Hamada K, Nagai S, Tanaka S, et al: Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 650-656. (Pubitemid 46446853)
13. Gläser S, Noga O, Koch B, et al: Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. Respir Med 2009; 103: 317-324.
14. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galiè N, Hoeper MM, Humbert M, et al: Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
15. Arcasoy SM, Christie JD, Ferrari VA, et al: Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167: 735-740. (Pubitemid 36801751)
16. Nathan SD, Shlobin OA, Barnett SD, et al: Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008; 102: 1305-1310.
17. Weitzenblum E, Ehrhart M, Rasaholinjanahary J, Hirth C: Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration 1983; 44: 118-127. (Pubitemid 13189310)
18. Hawrylkiewicz I, Izdebska-Makosa Z, Grebska E, et al: Pulmonary haemodynamics at rest and on exercise in patients with idiopathic pulmonary fibrosis. Bull Eur Physiopathol Respir 1982; 18: 403-410. (Pubitemid 12117073)
19. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD: Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007; 30: 715-721. (Pubitemid 351194832)
20. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM: Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 659-664. (Pubitemid 44395333)
21. Modrykamien AM, Gudavalli R, McCarthy K, Parambil J: Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis. Respir Care 2010; 55: 584-588.
22. Papakosta D, Dimadi M, Stagaki E, et al, on behalf of the Hellenic ILD group: Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis; a multicenter study. Eur Respir J 2007; 30:P818.
23. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD: Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131: 657-663. (Pubitemid 46446854)
24. Nathan SD, Shlobin OA, Ahmad S, et al: Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008; 76: 288-294.
25. Nathan SD, Noble PW, Tuder RM: Idiopathic pulmonary fibrosis and pulmonary hypertension: Connecting the dots. Am J Respir Crit Care Med 2007; 175: 875-880. (Pubitemid 46684695)
26. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD: Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 2007; 82: 342-350. (Pubitemid 46348935)
27. Renzoni EA, Walsh DA, Salmon M, et al: Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 2003; 167: 438-443. (Pubitemid 36216429)
28. Kim KH, Maldonado F, Ryu JH, et al: Iron deposition and increased alveolar septal capillary density in nonfibrotic lung tissue are associated with pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Res 2010; 11: 37.
29. Turner-Warwick M: Precapillary systemicpulmonary anastomoses. Thorax 1963; 18: 225-237.
30. Ebina M, Shimizukawa M, Shibata N, et al: Heterogeneous increase in cd34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169: 1203-1208. (Pubitemid 38680397)
31. Magro CM, Waldman WJ, Knight DA, et al: Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies. Hum Immunol 2006; 67: 284-297. (Pubitemid 43729356)
32. Antoniou KM, Tzouvelekis A, Alexandrakis MG, et al: Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest 2006; 130: 982-988. (Pubitemid 44583725)
33. Gagermeier J, Dauber J, Yousem S, Gibson K, Kaminski N: Abnormal vascular phenotypes in patients with idiopathic pulmonary fibrosis and secondary pulmonary hypertension. Chest 2005; 128(6 suppl):601S. (Pubitemid 43054149)
34. Naeije R, Barberà JA: Pulmonary hypertension associated with COPD. Crit Care 2001; 5: 286-289. (Pubitemid 34130319)
35. Trakada G, Nikolaou E, Pouli A, et al: Endothelin- 1 levels in interstitial lung disease patients during sleep. Sleep Breath 2003; 7: 111-118.
36. Corte TJ, Wort SJ, Wells AU: Pulmonary hypertension in idiopathic pulmonary fibrosis: A review. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 7-19.
37. Pouwels-Fry S, Pouwels S, Fournier C, et al: Effects of oxygen on exercise-induced increase of pulmonary arterial pressure in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25: 133-139.
38. Patel NM, Lederer DJ, Borczuk AC, Kawut SM: Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007; 132: 998-1006.
39. Charbeneau RP, Peters-Golden M: Eicosanoids: Mediators and therapeutic targets in fibrotic lung disease. Clin Sci (Lond) 2005; 108: 479-491. (Pubitemid 40827555)
40. Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF: 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 1998; 157: 219-229. (Pubitemid 28071286)
41. Tuder RM, Cool CD, Geraci MW, et al: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1998; 159: 1925-1932.
42. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415. (Pubitemid 18090241)
43. Fonseca C, Abraham D, Renzoni EA: Endothelin in pulmonary fibrosis. Am J Respir Cell Mol Biol 2011; 44: 1-10.
44. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q: Expression of endothelin- 1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341: 1550-1554. (Pubitemid 23170459)
45. Uguccioni M, Pulsatelli L, Grigolo B, et al: Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol 1995; 48: 330-334.
46. Reichenberger F, Schauer J, Kellner K, Sack U, Stiehl P, Winkler J: Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001; 179: 163-174. (Pubitemid 34033112)
47. Saleh D, Furukawa K, Tsao MS, et al: Elevated expression of endothelin-1 and endothelin- converting enzyme-1 in idiopathic pulmonary fibrosis: Possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997; 16: 187-193. (Pubitemid 127498240)
48. Barst RJ, McGoon M, Torbicki A, et al: Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 40S-47S. (Pubitemid 38759716)
49. Mermigkis C, Stagaki E, Tryfon S, et al: How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis? Sleep Breath 2010; 14: 387-390.
50. Nathan SD, Basavaraj A, Reichner C, et al: Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med 2010; 104: 1035-1041.
51. Ng CS, Wells AU, Padley SP: A CT sign of chronic pulmonary arterial hypertension: The ratio of main pulmonary artery to aortic diameter. J Thorac Imaging 1999; 14: 270-278. (Pubitemid 29470994)
52. Zisman DA, Karlamangla AS, Ross DJ, et al: High-resolution CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007; 132: 773-779.
53. Resten A, Maitre S, Humbert M, et al: Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. Am J Roentgenol 2004; 183: 65-70. (Pubitemid 38789013)
54. Todd NW, Lavania S, Park MH, et al: Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia. J Heart Lung Transplant 2010; 29: 188-194.
55. Zisman DA, Ross DJ, Belperio JA, et al: Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2007; 101: 2153-2159. (Pubitemid 47324243)
56. Zisman DA, Karlamangla AS, Kawut SM, et al: Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2008; 133: 640-645. (Pubitemid 351367371)
57. Ghanem MK, Makhlouf HA, Agmy GR, Imam HM, Fouad DA: Evaluation of recently validated non-invasive formula using basic lung functions as new screening tool for pulmonary hypertension in idiopathic pulmonary fibrosis patients. Ann Thorac Med 2009; 4: 187-196.
58. Cottin V, Le Pavec J, Prévot G, et al: Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35: 105-111.
59. Mejía M, Carrillo G, Rojas-Serrano J, et al: Idiopathic fibrosis and emphysema: Decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136: 10-15.
60. Bouros D: Combined pulmonary fibrosis and emphysema syndrome. Pneumon 2009; 22: 128-130.
61. Cottin V, Nunes H, Brillet P, et al: Combined pulmonary fibrosis and emphysema: A distinct underrecognised entity. Eur Respir J 2005; 26: 586-593. (Pubitemid 41448654)
62. Aduen JF, Zisman DA, Mobin SI, et al: Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: Implications for the diagnosis of combined obstructive and restrictive lung disease. Mayo Clin Proc 2007; 82: 48-54. (Pubitemid 46043228)
63. Fell CD, Liu LX, Motika C, et al: The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 402-407.
64. Strange C, Highland KB: Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2005; 11: 452-455. (Pubitemid 41291091)
65. Ferrazza AM, Martolini D, Valli G, Palange P: Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. Respiration 2009; 77: 3-17.
66. Papadopoulos CE, Pitsiou G, Karamitsos TD, et al: Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: A tissue Doppler echocardiographic study. Eur Respir J 2008; 31: 701-706.
67. Kawut SM, O'Shea MK, Bartels MN, Wilt JS, Sonett JR, Arcasoy SM: Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med 2005; 99: 1431-1439. (Pubitemid 41487501)
68. Boutou AK, Pitsiou G, Trigonis I, et al: Exercise capacity in idiopathic pulmonary fibrosis: The effect of pulmonary hypertension. Respirology 2011; 16: 451-458.
69. Schiller NB: Pulmonary artery pressure estimation by Doppler and two-dimensional echocardiography. Cardiol Clin 1990; 8: 277-287. (Pubitemid 20292988)
70. Swanson KL, Utz JP, Krowka MJ: Doppler echocardiography-right heart catheterization relationships in patients with idiopathic pulmonary fibrosis and suspected pulmonary hypertension. Med Sci Monit 2008; 14:CR177-CR182. (Pubitemid 351520820)
71. Hoeper MM, Lee SH, Voswinckel R, et al: Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546-2552. (Pubitemid 44881214)
72. Behr J, Ryu JH: Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008; 31: 1357-1367.
73. Yap LB, Mukrejee D, Timms PM, Ashrafian H, Coghlan JG: Natriuretic peptides, respiratory disease, and the right heart. Chest 2004; 126: 1330-1336. (Pubitemid 39391268)
74. Leuchte HH, Neurohr C, Baumgartner RA, et al: Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170: 360-365. (Pubitemid 39214607)
75. Leuchte HH, Baumgartner RA, El-Nounou ME, et al: Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173: 744-750.
76. Leuchte HH, El-Nounou ME, Tuerpe JC, et al: N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007; 131: 402-409. (Pubitemid 46280399)
77. Wieshammer S, Dreyhaupt J, Basler B, Marsovszky E: NT-proBNP for pulmonologists: Not only a rule-out test for systolic heart failure but also a global marker of heart disease. Respiration 2009; 77: 370-380.
78. Song JW, Song JK, Kim DS: Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med 2009; 103: 180-186.
79. Corte TJ, Wort SJ, Gatzoulis MA, Engel R, Giannakoulas G, Macdonald PM, Wells AU: Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J 2010; 36: 819-825.
80. Swigris JJ, Swick J, Wamboldt FS, et al: Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest 2009; 136: 841-848.
81. Corte TJ, Wort SJ, Gatzoulis MA, et al: Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax 2009; 64: 883-888.
82. Pitsiou G, Papadopoulos CE, Karvounis HI, et al: Utility of tissue Doppler imaging in predicting outcome in patients with idiopathic pulmonary fibrosis. Hellenic J Cardiol 2007; 48: 143-151. (Pubitemid 47621083)
83. Bando K, Keenan RJ, Paradis IL, et al: Impact of pulmonary hypertension on outcome after single-lung transplantation. Ann Thorac Surg 1994; 58: 1336-1342. (Pubitemid 24347521)
84. Harari S, Simonneau G, De Juli E, et al: Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant 1997; 16: 460-463. (Pubitemid 27199604)
85. Huerd SS, Hodges TN, Grover FL, et al: Secondary pulmonary hypertension does not adversely affect outcome after single lung transplantation. J Thorac Cardiovasc Surg 2000; 119: 458-465. (Pubitemid 30146524)
86. Fitton TP, Kosowski TR, Barreiro CJ, et al: Impact of secondary pulmonary hypertension on lung transplant outcome. J Heart Lung Transplant 2005; 24: 1254-1259. (Pubitemid 41247807)
87. Whelan TP, Dunitz JM, Kelly RF, et al: Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005; 24: 1269-1274. (Pubitemid 41247809)
88. Fell CD, Martinez FJ: The impact of pulmonary arterial hypertension on idiopathic pulmonary fibrosis. Chest 2007; 131: 641-643. (Pubitemid 46446849)
89. Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
90. McLaughlin VV, McGoon MD: Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431. (Pubitemid 44454562)
91. Olschewski H, Ghofrani HA, Walmrath D, et al: Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160: 600-607. (Pubitemid 29380679)
92. Strange C, Bolster M, Mazur J, et al: Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 2000; 118: 1077-1082.
93. Ghofrani HA, Wiedemann R, Rose F, et al: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial. Lancet 2002; 360: 895-900. (Pubitemid 35283832)
94. Saggar R, Shapiro SS, Ross DJ, et al: Treprostinil to reverse pulmonary hypertension associated with idiopathic pulmonary fibrosis as a bridge to single-lung transplantation. J Heart Lung Transplant 2009; 28: 964-967.
95. Yung GL, Kriett JM, Jamieson SW, et al: Outpatient inhaled nitric oxide in a patient with idiopathic pulmonary fibrosis: A bridge to lung transplantation. J Heart Lung Transplant 2001; 20: 1224-1227. (Pubitemid 33035085)
96. Galie N, Ghofrani HA, Torbicki A, et al: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157. (Pubitemid 41653106)
97. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA: Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131: 897-899. (Pubitemid 46446887)
98. Madden BP, Sheth A, Wilde M, Ong YE: Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease? Vascul Pharmacol 2007; 47: 184-188. (Pubitemid 47096872)
99. Chapman TH, Wilde M, Sheth A, Madden BP: Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use? Vascul Pharmacol 2009; 51: 90-95.
100. The Idiopathic Pulmonary Fibrosis Clinical Research Network: A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363: 620-628.
101. Channick RN, Simonneau G, Sitbon O, et al: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo- controlled study. Lancet 2001; 358: 1119-1123. (Pubitemid 32971843)
102. Rubin LJ, Badesch DB, Barst RJ, et al: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903. (Pubitemid 34984638)
103. Günther A, Enke B, Markart P, et al: Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: An open label study. Eur Respir J 2007; 29: 713-719. (Pubitemid 46554621)
104. King TE Jr, Behr J, Brown KK, et al: BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
105. Raghu G, King TE Jr, Behr J, et al: Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010; 35: 118-123.
106. Orens JB, Estenne M, Arcasoy S, et al: International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-755. (Pubitemid 43963375)
107. Conte JV, Borja MJ, Patel CB, Yang SC, Jhaveri RM, Orens JB: Lung transplantation for primary and secondary pulmonary hypertension. Ann Thorac Surg 2001; 72: 1673-1679.
108. Christie JD, Edwards LB, Aurora P, et al: The Registry of the International Society for Heart and Lung Transplantation: Twenty- sixth Official Adult Lung and Heart- Lung Transplantation Report - 2009. J Heart Lung Transplant 2009; 28: 1031-1049.